- Joined
- Mar 7, 2018
- Messages
- 55,377
- Reaction score
- 15,768
- Location
- Lower Mainland of BC
- Gender
- Male
- Political Leaning
- Centrist
From ABC News
Lisa Crook was lucky. She saved $800 last year after her insurance company started covering a new, less expensive insulin called Basaglar that was virtually identical to the brand she had used for years.
The list price for Lantus, a long-acting insulin made by Sanofi that she injected once a day, had nearly quadrupled over a decade.
With Basaglar, “I’ve never had my insulin cost drop so significantly,” said Crook, a legal assistant in Dallas who has Type 1 diabetes.
But many people with diabetes can’t get the deal Crook got. In a practice that policy experts say smothers competition and keeps prices high, drug companies routinely make hidden pacts with middlemen that effectively block patients from getting cheaper generic medicines.
Such agreements “make it difficult for generics to compete or know what they’re competing against,” said Stacie Dusetzina, an associate professor of health policy at Vanderbilt University School of Medicine.
COMMENT:-
Somehow I can't quite follow the logic involved when [a] the actual price paid to the drug companies go down (subtract the rebate [which increases from year to year] from the list price [which increases from year to year]) while the cost to the consumer goes up (add the markup [which increases from year to year] to the list price [which increases from year to year]).
Secretive 'rebate trap' keeps generic drugs for diabetes and other ills out of reach
Lisa Crook was lucky. She saved $800 last year after her insurance company started covering a new, less expensive insulin called Basaglar that was virtually identical to the brand she had used for years.
The list price for Lantus, a long-acting insulin made by Sanofi that she injected once a day, had nearly quadrupled over a decade.
With Basaglar, “I’ve never had my insulin cost drop so significantly,” said Crook, a legal assistant in Dallas who has Type 1 diabetes.
But many people with diabetes can’t get the deal Crook got. In a practice that policy experts say smothers competition and keeps prices high, drug companies routinely make hidden pacts with middlemen that effectively block patients from getting cheaper generic medicines.
Such agreements “make it difficult for generics to compete or know what they’re competing against,” said Stacie Dusetzina, an associate professor of health policy at Vanderbilt University School of Medicine.
COMMENT:-
Somehow I can't quite follow the logic involved when [a] the actual price paid to the drug companies go down (subtract the rebate [which increases from year to year] from the list price [which increases from year to year]) while the cost to the consumer goes up (add the markup [which increases from year to year] to the list price [which increases from year to year]).